Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.76 |
| ▸ | METAP1 | P53582 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CCR4 | P51679 | 1/20 | 0.52 |
| ▸ | NCF1 | P14598 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | ACACA | Q13085 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 1/20 | 0.46 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16103034 | 0.99 | L3MBTL1 (0.74) | L3MBTL1KDM4EMETAP1CYP2C9RAD52 | |
| Hydrochloric Acid SCHEMBL20450129 | 0.99 | L3MBTL1 (0.74) | L3MBTL1KDM4EMETAP1CYP2C9RAD52 | |
| SCHEMBL16123720 | 0.88 | KDM4E (0.61) | L3MBTL1KDM4EMETAP1CYP2C9RAD52 | |
| Hydrochloric Acid SCHEMBL18093576 | 0.87 | KDM4E (0.60) | L3MBTL1KDM4EMETAP1CYP2C9RAD52 | |
| Hydrochloric Acid SCHEMBL18093601 | 0.87 | KDM4E (0.60) | L3MBTL1KDM4EMETAP1CYP2C9RAD52 | |
| SCHEMBL9437189 | 0.87 | L3MBTL1 (1.00) | L3MBTL1KDM4EMETAP1MEN1KMT2A | |
| SCHEMBL16123668 | 0.82 | KDM4E (0.70) | L3MBTL1KDM4EMETAP1MEN1KMT2A | |
| SCHEMBL5999862 | 0.82 | KDM4E (0.70) | L3MBTL1KDM4EMETAP1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL16098559 | 0.81 | KDM4E (0.68) | L3MBTL1KDM4EMETAP1MEN1KMT2A | |
| SCHEMBL16102110 | 0.78 | CYP2C9 (0.50) | L3MBTL1KDM4ECYP2C9RAD52CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA (FR) | 2019-01-15 | — | — | US | claimed |
| EP-2976333-B1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA SAS (FR) | 2018-08-08 | — | — | EP | claimed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | claimed |
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA (FR) | 2019-01-15 | — | — | US | disclosed |
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA (FR) | 2019-01-15 | — | — | US | disclosed |
| EP-2976333-B1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA SAS (FR) | 2018-08-08 | — | — | EP | disclosed |
| EP-2976333-B1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA SAS (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| WO-2014147611-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | NQO2, MKI67, NQO1 | L3MBTL1 3884/4885KDM4E 979/4885METAP1 4000/4885 |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | NQO2, MKI67, NQO1 | L3MBTL1 3884/4885KDM4E 979/4885METAP1 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.